NovaBay Pharmaceuticals, Inc.'s (NBY) President and CEO Ron Najafi, Ph.D., will present at the Rodman & Renshaw 17th Annual Global Investment Conference on Thursday, September 10, 2015 at 3:25 p.m. Eastern time (12:25 p.m. Pacific time). The conference is being held at the St. Regis Hotel in New York City.
A live webcast and replay of the company's presentation will be available on NBY's website at http://novabay.com/investors/events.
Last week, NBY announced that its Avenova(TM), the only lid & lash product containing Neutrox, will be marketed in New Zealand through a partnership with Ophthalmic Instrument Company. NBY's Avenova is already in China, Southeast Asia and the Middle East.
Neutrox is NBY's proprietary pure hypochlorous acid without any sodium hypochlorite impurities. Hypochlorous acid is naturally produced by white blood cells to fight microbial invaders.
According to NBY, lab tests show that its proprietary formulation of hypochlorous acid is effective in solution both at killing microbes and at neutralizing the bacterial enzymes and toxins that contribute to common eye conditions like blepharitis, meibomian gland dysfunction and associated dry eye
NBY recently reported second quarter 2015 revenue of $1.0 million, compared to $123,000 in the same period the prior year. NBY said that the increase was due to the sales of Avenova, which was commercially launched in August 2014. NBY's Avenova sales increased 73% versus the first quarter of 2015
NBY is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX(TM) Family of Products, cleared by the US FDA as a 510(k) medical device; the NEUTROX Family of Products includes AVENOVA for the eye care market and NEUTROPHASE(R) for wound care, and CELLERX(TM) for the cosmetic surgery and aesthetic dermatology market; and its AGANOCIDE(R) compounds, led by AURICLOSENE(TM) which is in development as a new drug in urology and dermatology.
NBY has partnerships in the U.S. and around the world with PBE, Inc. (U.S.), IHT, Inc. (U.S.), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (South Korea), Biopharm (North African and the Middle East), Sarmedic Ltd (Israel) and Alpha Pharma LLC (the Ukraine).
More about NovaBay Pharmaceuticals, Inc. (NBY) at www.novabay.com
**
Shares of Palo Alto Networks, Inc. (PANW) climbed more than 4.5% in after-hours trading Wednesday as the company delivered stronger-than-expected quarterly financial results.
For its fourth quarter fiscal 2015, PANW posted record revenue of $283.9 million, a 59% increase year over year, and non-GAAP net income $25.0 million, or $0.28 per diluted share, compared to non-GAAP net income of $9.1 million, or $0.11 per diluted share in the same quarter the prior year, topping the Capital IQ Consensus Estimate of $0.25 earnings per share on revenues of $256.55 million for the period.
According to its business outlook for the first quarter fiscal 2016, PANW expects total revenue to be in the range of $280 million to $284 million, representing year-over-year growth between 46% and 48%, and non-GAAP earnings per diluted share to be in the range of $0.31 to $0.32, also surpassing the Capital IQ Consensus Estimate of $0.30 earnings per share on revenues of $269.78 million for the period
PANW is the next-generation security company, leading a new era in cybersecurity by safely enabling applications and preventing cyber breaches for tens of thousands of organizations worldwide.
More about Palo Alto Networks, Inc. (PANW) at www.paloaltonetworks.com.
**
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE PR Finance www.finance.crwe-pr.com/disclaimer
A live webcast and replay of the company's presentation will be available on NBY's website at http://novabay.com/investors/events.
Last week, NBY announced that its Avenova(TM), the only lid & lash product containing Neutrox, will be marketed in New Zealand through a partnership with Ophthalmic Instrument Company. NBY's Avenova is already in China, Southeast Asia and the Middle East.
Neutrox is NBY's proprietary pure hypochlorous acid without any sodium hypochlorite impurities. Hypochlorous acid is naturally produced by white blood cells to fight microbial invaders.
According to NBY, lab tests show that its proprietary formulation of hypochlorous acid is effective in solution both at killing microbes and at neutralizing the bacterial enzymes and toxins that contribute to common eye conditions like blepharitis, meibomian gland dysfunction and associated dry eye
NBY recently reported second quarter 2015 revenue of $1.0 million, compared to $123,000 in the same period the prior year. NBY said that the increase was due to the sales of Avenova, which was commercially launched in August 2014. NBY's Avenova sales increased 73% versus the first quarter of 2015
NBY is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX(TM) Family of Products, cleared by the US FDA as a 510(k) medical device; the NEUTROX Family of Products includes AVENOVA for the eye care market and NEUTROPHASE(R) for wound care, and CELLERX(TM) for the cosmetic surgery and aesthetic dermatology market; and its AGANOCIDE(R) compounds, led by AURICLOSENE(TM) which is in development as a new drug in urology and dermatology.
NBY has partnerships in the U.S. and around the world with PBE, Inc. (U.S.), IHT, Inc. (U.S.), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (South Korea), Biopharm (North African and the Middle East), Sarmedic Ltd (Israel) and Alpha Pharma LLC (the Ukraine).
More about NovaBay Pharmaceuticals, Inc. (NBY) at www.novabay.com
**
Shares of Palo Alto Networks, Inc. (PANW) climbed more than 4.5% in after-hours trading Wednesday as the company delivered stronger-than-expected quarterly financial results.
For its fourth quarter fiscal 2015, PANW posted record revenue of $283.9 million, a 59% increase year over year, and non-GAAP net income $25.0 million, or $0.28 per diluted share, compared to non-GAAP net income of $9.1 million, or $0.11 per diluted share in the same quarter the prior year, topping the Capital IQ Consensus Estimate of $0.25 earnings per share on revenues of $256.55 million for the period.
According to its business outlook for the first quarter fiscal 2016, PANW expects total revenue to be in the range of $280 million to $284 million, representing year-over-year growth between 46% and 48%, and non-GAAP earnings per diluted share to be in the range of $0.31 to $0.32, also surpassing the Capital IQ Consensus Estimate of $0.30 earnings per share on revenues of $269.78 million for the period
PANW is the next-generation security company, leading a new era in cybersecurity by safely enabling applications and preventing cyber breaches for tens of thousands of organizations worldwide.
More about Palo Alto Networks, Inc. (PANW) at www.paloaltonetworks.com.
**
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE PR Finance www.finance.crwe-pr.com/disclaimer
